Skip to main content
. 2019 Oct 14;37(34):3291–3299. doi: 10.1200/JCO.19.01389

FIG 3.

FIG 3.

Survival in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) treated with pembrolizumab. (A) Progression-free survival measured from first dose to first documented disease progression or death from any cause among 21 patients (KEYNOTE-013) and 53 patients (KEYNOTE-170) with rrPMBCL who received pembrolizumab. The estimated rates of patients alive and progression free at 12 months were 47% (KEYNOTE-013) and 38% (KEYNOTE-170), with median progression-free survival times of 10.4 months (95% CI, 3.4 months to not reached) among patients in KEYNOTE-013 and 5.5 months (95% CI, 2.8 to 12.1 months) among patients in KEYNOTE-170. (B) Overall survival measured from first dose to death from any cause. The estimated rates of overall survival at 12 months were 65% (KEYNOTE-013) and 58% (KEYNOTE-170), with median overall survival times of 31.4 months (95% CI, 4.9 months to not reached) among patients in KEYNOTE-013 and not reached (95% CI, 7.3 months to not reached) in KEYNOTE-170.